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Abstract
Cardiovascular disease (CVD) is highly prevalent in the dialysis population, affect-
ing up to 60% of cohorts. Cardiovascular mortality rates are reported to be ~14 per 100 
patient-years, which are 10- to 20-fold greater than those of age- and gender-matched 
controls. CVD is the primary cause of death in up to 40% of dialysis patients in Australia, 
New Zealand and the United States. Dialysis patients endure a greater burden of both 
traditional risk factors for CVD and risk factors related to loss of kidney function that 
may account for the higher CVD morbidity and mortality. Many cardiology guidelines 
include chronic kidney disease (CKD) and end-stage kidney disease (ESKD) as coronary 
heart disease (CHD) risk equivalents. It is therefore important for clinicians to both rec-
ognise and optimise the cardiovascular health of patients receiving maintenance dialysis. 
This chapter will focus on risk factor modification, screening and prevention of CVD 
in dialysis patients.
Keywords: dialysis, end-stage kidney disease, cardiovascular disease, risk factors, screening, 
prevention
1. Introduction
Reduced kidney function (estimated or measured glomerular filtration rate <60 mL/min/1.73 m2) 
and proteinuria are independent predictors of future coronary events [1]. It is not surprising 
therefore that cardiovascular disease (CVD) is highly prevalent in the dialysis population, 
affecting up to 60% of cohorts [2]. It is also the most common cause of death in this group, 
accounting for up to 40% of deaths in dialysis patients globally [3–5]. In Australia and New 
Zealand, the incidence rate of cardiovascular mortality in peritoneal dialysis (PD) and hae-
modialysis (HD) patients is approximately 10 and 8 per 100 patient-years,  respectively, some 
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10- to 20-fold greater than that of age and gender-matched controls [6]. The most common 
causes of cardiovascular mortality are sudden cardiac death, myocardial infarction and cardiac 
failure [6].
The increased risks of cardiovascular events and mortality in dialysis patients is partly related 
to an increased prevalence of traditional cardiovascular risk factors, including diabetes melli-
tus, hypertension, obesity, physical inactivity, smoking and dyslipidaemia (Table 1). However, 
these factors account for less than 50% of the excess risk of cardiovascular disease [7], leading 
many researchers to explore the roles of non-traditional risk factors (Table 1). Some of these fac-
tors, including anaemia, fluid overload, hyperuricaemia and chronic inflammation, are directly 
related to loss of residual kidney function, leading to hormonal, fluid balance and uraemic toxin 
dysregulation. However, dialysis-specific factors may also contribute to this risk. For example, 
in HD patients, dialysis catheters, membrane exposure, endotoxaemia (from intestinal hypo-
perfusion or dialysis water) and more rapid loss of residual kidney function may contribute 
to inflammation, oxidative stress and myocardial stunning, which may ultimately increase 
the risk of CVD [8, 9]. Moreover, the intermittent nature of HD has been reported to be asso-
ciated with heightened risks of cardiovascular mortality, particularly sudden cardiac death, 





Older age (>45 in males; >55 in females)* Albuminuria*
Obesity* Chronic kidney disease*
Sedentary lifestyle* Hyperhomocysteinaemia*
Premature family history of CVD Chronic fluid overload*
Dyslipidaemia* Poor sleep*
Male gender CKD-MBD*
Mental stress and depression* Malnutrition*
Race (African Americans, South Asians)* Elevated fibrinogen*
Alcohol Low testosterone*
Menopause Lipoprotein A*
Left ventricular hypertrophy* Hyperuricaemia*
Uraemic toxins (e.g. indoxyl sulphate, p-cresyl sulphate)*
Endotoxaemia*
*Risk factors that are prevalent in the dialysis population.
CVD, cardiovascular disease; CKD-MBD, chronic kidney disease mineral and bone disease. Modified from [19].
Table 1. Traditional and non-traditional cardiovascular risk factors.
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overload and electrolyte disturbances [10, 11]. On the other hand, PD patients may experience 
inflammation and oxidative stress as a result of exposure to PD catheters, bio-incompatible 
PD solutions and PD-related peritonitis [12]. Abnormalities in serum potassium concentra-
tions, particularly hypokalaemia, also disproportionately increase the risk of death in patients 
receiving PD [13]. Excessive exposure to glucose in PD solutions (up to 200 g/day) has also 
been linked to atherogenic lipid profiles, metabolic syndrome and ultimately increased CVD 
risk [14]. Jiang et al. noted that while ~22% of patients with end-stage kidney disease (ESKD) 
met the diagnostic criteria for metabolic syndrome pre-dialysis, this number rose to ~70% after 
commencement of PD. Similar results were reported by Johnson et al. [15]. Metabolic syndrome 
is an independent predictor of cardiovascular mortality in the PD population [16–18].
This chapter will focus on risk factor modification, screening and prevention of CVD in dialysis 
patients.
2. Risk factor modification
Whilst there is substantial research identifying the myriad CVD risk factors inherent in the dial-
ysis population, there is less to support that treatment of the modifiable factors alters outcomes 
to the same extent as in the non-CKD population. The evidence surrounding CVD risk fac-
tor modification in dialysis patients is summarised below. Clinical practice guideline recom-
mendations from National Kidney Foundation Kidney Disease Outcomes Quality Initiative 
(KDOQI), Kidney Disease: Improving Global Outcomes (KDIGO) and the International 
Society for Peritoneal Dialysis (ISPD) have been included where appropriate.
3. Traditional risk factors
3.1. Hypertension
There is marked heterogeneity in the definition, measurement methods and epidemiology 
of hypertension in dialysis populations. The 2004 KDOQI guidelines define hypertension 
as pre-dialysis blood pressure (BP) > 140/90 mmHg or post-dialysis BP > 130/80 mmHg [20]. 
However, pre- and post-dialysis BP readings considerably over and underestimate inter-dia-
lytic ambulatory BP respectively [21]. Ambulatory BP monitoring (ABPM) provides informa-
tion on circadian variation, is reproducible and remains the most reliable method to diagnose 
hypertension in the dialysis population [22, 23]. Home BP recordings, including ABPM 
and self-measured readings have been shown to be greater predictors of all-cause and cardio-
vascular mortality than haemodialysis unit recordings [24].
The definitions of hypertension clearly have a bearing on its reported epidemiology. The prev-
alence of hypertension—when defined by weekly average pre-dialysis systolic blood pres-
sure (BP) measures > 150/85 mmHg or the use of antihypertensive medications—was 86% 
among 2535 chronic HD patients in a multi-centre trial [25]. The prevalence of hypertension 
in another cohort—defined by inter-dialytic ambulatory BP measures ≥ 135/85 mmHg or 
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the prescription of any antihypertensive agent—was 82% among 369 chronic HD patients 
[26]. The prevalence of hypertension in PD populations varies from 69 to 88% (when defined 
as ≥140/90 mmHg) [27].
Guidelines, epidemiological studies and clinical decision-making should therefore not rely 
on peri-dialysis BP readings alone. Regardless of definition, hypertension remains very com-
mon in the dialysis population and an important modifiable risk factor.
The pathophysiology of hypertension is multifaceted, complex and unique in dialysis 
patients. Volume and sodium overload remain the predominant mechanisms of hyperten-
sion, with a graded increase in BP as fluid and sodium (and body weight) accumulate over 
the inter-dialytic period [28]. Sodium and volume removal through dialysis manages hyper-
tension in a proportion of patients. Lins et al. showed that atrial natriuretic peptide concentra-
tions decrease post dialysis in those patients whose BP responded to ultrafiltration [29]. Other 
reported mechanisms include increased arterial stiffness [30], renin-angiotensin-aldosterone 
system activation [31], sympathetic hyperactivity [32, 33], endothelial dysfunction [34, 35], 
sleep apnoea [36] and use of erythropoiesis-stimulating agents (ESAs) [37, 38].
Non-pharmacological measures to treat hypertension ultimately involve sodium and fluid 
restriction. Ultrafiltration, sodium removal and reduction of dry weight result in normalisation 
of the BP in ~60% of chronic dialysis patients [39]. Establishment and attainment of the patient’s 
dry weight are the generally accepted initial goals. The dry weight has been defined as the low-
est tolerated post-dialysis weight, achieved gently and gradually, at which patients experience 
minimal signs or symptoms of dysvolaemia [40]. Furthermore, the duration of dialysis treatment 
should be long enough to ensure that the required ultrafiltration (and BP control) can be attained 
with minimal symptoms and haemodynamic compromise. Increased duration of dialysis affords 
a slower rate of ultrafiltration, improves BP control and reduces the incidence of intra-dialytic 
hypotension [41, 42]. Minimisation of inter- and intra-dialytic sodium gain is essential to man-
agement also. KDOQI guidelines advocate a low dietary sodium intake (<2–3 g/day), which 
appears to be effective in limiting thirst, reducing inter-dialytic weight gain, achievement of dry 
weight and controlling BP [43]. Similarly, avoidance of a positive sodium balance during dialysis 
is also key, i.e., dialysate sodium concentrations should not exceed that of pre-dialysis serum 
sodium. Individualisation of the dialysate sodium prescription was shown to reduce intra-dia-
lytic weight gain, thirst and episodes of intra-dialytic hypotension in a randomised, cross-over 
study [44]. Use of a low sodium PD solution has also shown promise, with increased diffusive 
sodium removal, reduced thirst, improved ultrafiltration and reduction in BP [45].
Pharmacological therapies have been shown to be effective in achieving BP control in dialysis 
patients. Importantly, pharmacological treatment of hypertension has been shown to mod-
ify CVD outcomes in the dialysis population. In a systematic review and meta-analysis of 8 
randomised, controlled trials (RCTs) involving 1679 dialysis patients and 495 cardiovascular 
events (CVE), lowering BP with medication was associated with decreased risks of CVE (RR 
0.71, 0.55–0.92, p = 0.009), all-cause mortality (RR 0.80, 0.66–0.96, p = 0.014) and cardiovascular 
mortality (RR 0.71, 0.50–0.99, p = 0.044) [46]. If these results were broadly applicable to dialysis 
populations, BP treatment would be expected to prevent 2 deaths per 100 patient-years.
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Angiotensin receptor blockers (ARBs) have been shown to reduce CVE in ESKD [47–49]. 
Suzuki et al. found that HD patients randomised to candesartan, valsartan or losartan had 
fewer fatal and non-fatal CVE (hazard ratio (HR) 0.51, 0.33–0.79, p = 0.002) [47]. Similar 
results were seen with telmisartan in HD patients with congestive heart failure—with 
reductions in all-cause mortality (HR 0.51, 0.32–0.82, p < 0.01), cardiovascular mortality (HR 
0.42, 0.38–0.61, p < 0.0001) and hospital stay (HR 0.38, 0.19–0.51, p < 0.0001).
Angiotensin-converting enzyme inhibitors (ACEi) have been studied in RCTs including dialy-
sis patients. Whilst effective antihypertensive agents, ACEi have not been shown to reduce 
CVE compared with standard therapy. Zannad et al. found no significant benefit of fosino-
pril in HD patients after adjusting for independent predictors of CVE [50]. Li et al. showed 
that ramipril, whilst slowing residual kidney function decline in PD patients, did not reduce 
the risk of CVEs [51]. In a prospective, open-label RCT of lisinopril versus atenolol adminis-
tered three times a week after maintenance HD in 200 prevalent patients with hypertension 
and left ventricular hypertrophy followed for 12 months. Agarwal et al. [52] reported that 
lisinopril-based therapy resulted in higher rates of serious CVE (incidence rate ratio [IRR] 
2.36, 95% CI 1.36–4.23) and all-cause hospitalizations (IRR 1.61, 95% CI 1.18–2.19). Moreover, 
a systematic review of 8 RCTs of renin angiotensin aldosterone inhibitors (RAAS inhibitors—2 
ACEi, 4 ARBs, 2 ACEi versus ARBs) did not find a clear role for these agents in hypertensive 
HD patients [53]. Unfortunately, the small numbers of patients and trials as well as subopti-
mal methodologic quality severely limit the conclusions that can be drawn about these agents 
for preventing CVD in dialysis patients.
Mineralocorticoid antagonists (MCAs) are another form of RAAS inhibitor that may mitigate 
cardiovascular risk in dialysis patients. Quach et al. [54] recently reported a systematic review 
and meta-analysis of 9 RCTs involving 829 dialysis patients (peritoneal dialysis or haemodi-
alysis) treated with MCAs (spironolactone 8 trials, eplerenone 1 trial). Compared with con-
trol patients, those treated with MCAs had a significantly lower cardiovascular mortality 
(risk ratio [RR] 0.34, 95% CI 0.15–0.75) and all-cause mortality (RR 0.40, 95% CI 0.23–0.69), 
although these benefits were offset by a significantly increased risk of hyperkalaemia (RR 
3.05, 95% CI 1.21–7.70). Given the small sample sizes and generally poor quality of published 
trials, the relative benefits and harms of RAAS inhibitors, including MCAs, for preventing 
CVD in dialysis patients remain uncertain. An adequately powered RCT is warranted given 
the possible benefit shown in the small studies to date.
The roles of other specific anti-hypertensive agents also remain uncertain. Tepel et al. found 
that whilst amlodipine did not significantly reduce all-cause mortality, it may reduce CVE 
(composite secondary end-point, HR 0.53, 0.31–0.93, p = 0.03) in HD patients [55]. Cice et al. 
showed that carvedilol improved LV function and reduced all-cause mortality (HR 0.51, 
0.32–0.82, p < 0.01), cardiovascular mortality (HR 0.32, 0.18–0.57, p < 0.0001) and hospital 
admissions (HR 0.44, 0.25–0.77, p < 0.005) in 114 HD patients with dilated cardiomyopathy 
over 2 years at a single centre [56]. These findings have yet to be replicated. Indeed, a recently 
published feasibility study demonstrated significant challenges with recruiting dialysis 
patients into β-blocker intervention studies and emphasized the need for pragmatic trial 
methodologies [57].
Cardiovascular Disease in Dialysis Patients
http://dx.doi.org/10.5772/intechopen.70362
63
The current KDOQI and ISPD recommendations of a BP target goal < 140/90 mmHg are 
extrapolated from studies in the non-dialysis population [20]. There have been no published 
prospective, randomised trials to date evaluating the target BP in dialysis patients. Target BP 
and appropriate treatment options need to therefore be individualised based on patient co-
morbidities, residual kidney function, dialysis modality and symptoms.
3.2. Diabetes
Diabetic nephropathy remains the leading cause of ESKD globally, with the number of dia-
betic patients commencing dialysis increasing [3, 58–60]. When diabetes is the primary cause 
of ESKD, 5-year adjusted survival is only 38%, significantly lower than if hypertension (45%) 
or glomerulonephritis (55%) is the primary aetiology [61]. Diabetic patients on HD are at 
a higher risk of CVD, especially acute myocardial infarction (OR 1.36) and cardiac death (OR 
1.88) [62, 63].
There is currently a paucity of high quality, randomised trials evaluating the effect of glycae-
mic control on outcomes in the dialysis population. However, observational data indicates that 
survival is influenced by glycaemic control in patients with diabetic nephropathy. Patients 
with HbA1c < 7.5% (58.5 mmol/mol) at dialysis initiation had a greater 5-year survival than 
those with poor control (31.7% vs 12.1%, adjusted HR 1.13) [64]. In maintenance HD patients, 
those with a HbA1c < 8% (63.9 mmol/mol) had an improved survival rate at 3 and 5 years 
compared to the poor control group [65]. Very poor glycaemic control (HbA1c > 10% or > 85.8 
mmol/mol) is associated with higher adjusted all-cause and cardiac death (HR 1.41 and 1.73 
respectively) in HD patients and increased mortality (HR 1.20) in all dialysis patients [66, 67]. 
Furthermore, Ramirez et al. and Ricks et al. went on to find a U-shaped association between 
HbA1c and mortality [68, 69]. There was a symmetric increase in adjusted all-cause mortality 
with low HbA1c—6.0–6.9% (42.1–51.9 mmol/mol, HR 1.05), 5.0–5.9% (31.1–41.0 mmol/mol, 
HR 1.08) and ≤ 5.0% (≤31.1 mmol/mol, HR 1.35) [69].
However, HbA1c has its limitations as a marker of glycaemic control in ESKD. Metabolic aci-
dosis and elevated blood urea nitrogen have been shown to falsely elevate HbA1c whereas 
anaemia, ESA use, protein-energy wasting and shortened erythrocyte lifespan falsely decrease 
HbA1c values. Fructosamine and glycated albumin, as markers of intermediate-term glycae-
mic control, may therefore be more accurate metrics than HbA1c in ESKD patients [70].
KDOQI and KDIGO guidelines recognise the lack of robust evidence for glycaemic control 
and the limitations of HbA1C in ESKD [20] [KDIGO]. They currently recommend that indi-
viduals on dialysis and pre-dialysis, respectively, should target an HbA1C ~7% (53.0 mmol/
mol), with tighter control to be avoided in patients at risk of hypoglycaemia. Furthermore, 
the KDOQI guidelines advise clinicians that dosing of insulin and oral hypoglycaemic agents 
may change markedly as patients transition onto dialysis—often with increased requirements 
in PD [20]. The ISPD Guidelines recommend an HbA1c target of 7% (53 mmol/mol) in PD 
patients with diabetes, which may be increased up to 8.5% (69 mmol/mol) in older patients [71].
Minimising dialysis-related glucose exposure may also help to mitigate cardiovascular risk 
in diabetic PD patients. Several observational cohort studies have reported that higher  peritoneal 
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dialysis-related glucose exposure was associated with higher rates of technique failure and both 
cardiovascular and all-cause mortality [72–74]. A subsequent RCT of a glucose-sparing PD 
regimen (combination of dextrose-based solution, icodextrin and amino acids) versus conven-
tional PD (dextrose solutions only) in 251 diabetic PD patients over 6 months demonstrated 
that the glucose sparing regimen produced modest benefits in the outcomes of HbA1c (0.5% 
lower, 95% CI 0.1–0.8%), serum triglycerides, very low density lipoproteins and apolipoprotein 
B, although this was counterbalanced by a safety signal regarding a (not statistically significant) 
higher rate of deaths and serious adverse events, including several related to volume expan-
sion, in the glucose-sparing group [14]. The results suggested that glucose-sparing PD regimens 
may improve surrogate metabolic outcomes, albeit possibly at the expense of optimal perito-
neal ultrafiltration and fluid control. The ISPD Guidelines recommend that “once daily icodex-
trin be considered as the long-dwell dialysis solution in diabetic peritoneal dialysis patients 
for better glycaemic control” [71].
3.3. Cigarette smoking
Cigarette smoking is the leading cause of preventable death in the United States and ~30% is 
attributed to ischaemic heart disease [75]. The prevalence of smoking in the dialysis popula-
tion has been reported as high as 15% [76].
Liebman et al. conducted a systematic review and meta-analysis of smoking and cardiovas-
cular outcomes in dialysis patients. Whilst smokers had a significant increase in all-cause 
mortality (HR 1.65, 1.26–2.14, p < 0.001), surprisingly no significant increase was seen in car-
diovascular events (HR 1.01, 0.98–1.05, p = 0.4) compared with non-smokers [77]. The authors 
reconcile that this may be due to (a) the composite cardiovascular outcome not being influ-
enced by smoking alone and (b) that smoking may increase mortality via non-cardiovascular 
means.
Though specific data in dialysis patients are lacking, smoking cessation is likely to reduce car-
diovascular disease and mortality. Smoking cessation is supported by both KDOQI and ISPD 
guidelines, with recommendations for specialist referral if required [20, 71].
3.4. Dyslipidaemia
Dyslipidaemia has been extensively studied as a potentially modifiable risk factor in the pre-
vention of CVD in dialysis patients. Dyslipidaemia in ESKD presents predominantly with low 
high-density lipoprotein (HDL) and high triglyceride levels. Importantly, total cholesterol 
and low-density lipoprotein (LDL) levels tend to be in the normal range or even low [78]. 
The relationship between serum cholesterol levels and cardiovascular risk in the dialysis pop-
ulation is complex. Observational studies have shown an inverse relationship between total 
cholesterol and survival i.e. dialysis patients with the lowest cholesterol levels had the highest 
mortality rates [79–81]. However, this appears to be confounded by malnutrition and chronic 
inflammation—as when corrected for serum albumin, C-reactive protein and interleukin 6 
levels, the positive correlation between cholesterol and mortality parallels that of the non-
dialysis population [82].
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The pathophysiological role of cholesterol in atherosclerosis appears to differ in patients 
with ESKD. Coronary artery studies in the ESKD population have shown a 5-fold higher 
prevalence of calcification, greater deposition of inflammatory cytokines and more intense 
intra-plaque haemorrhage [78]. Fathi et al. studied the effect of aggressive cholesterol low-
ering in non-CKD and ESKD patients with established coronary artery disease (CAD) [83]. 
In the non-CKD group, the carotid artery intima/media thickness decreased significantly 
with atorvastatin therapy during the 2-year observation period. There was no such change 
seen in the ESKD cohort. The authors proposed that the beneficial effect of statins is likely 
counteracted or nullified by the uraemic state.
There is accumulation of highly atherogenic lipoproteins in dialysis patients due to deficiency 
of lipoprotein lipase, hepatic lipase and LDL receptor-related protein [84]. These include very 
low density lipoprotein (VLDL), small dense LDL, intermediate-density lipoproteins, oxi-
dised LDL and lipoprotein (a)—which are not treatable with statin therapy [84]. This athero-
genic lipid profile is also more apparent in PD patients than those on HD [85–87].
Atherosclerotic coronary artery disease only accounts for ~20% of CVD in ESKD [88]. Vascular 
calcification, LVH, diastolic dysfunction, cardiomyopathy, arrhythmia and sudden cardiac 
death are also contributory. Given that the majority of CVD mortality is not related to CAD, it 
seems plausible that lipid lowering therapy would not modify outcomes [84].
In the non-dialysis population, a meta-analysis of over 90,000 randomised patients demon-
strated an overall 25% reduction in major cardiovascular events for each 1 mmol/L decrease 
in LDL cholesterol [89].
However, treatment of dyslipidaemia does not appear to confer the same benefits 
in the dialysis population. Palmer et al. performed a systematic review of RCTs evaluating 
the efficacy of statins in over 8000 dialysis patients [90]. Despite clinically relevant lowering 
in serum cholesterol levels, statins had no significant effects on major cardiovascular events 
(RR 0.95, 0.88–1.03), all-cause mortality (RR 0.96, 0.90–1.02), cardiovascular mortality (RR 
0.94, 0.84–1.06) or myocardial infarction (RR 0.87, 0.71–1.07).
Hypertriglyceridaemia (fasting triglycerides > 5.65 mmol/L) should be treated through life-
style measures, including dietary modification, weight reduction, increased physical activity, 
adequate glycaemic control and reduced alcohol intake [KDIGO].
Given the evidence presented, the KDOQI and KDIGO guideline recommendations advise 
that statins should not be initiated routinely for primary prevention in dialysis patients 
[20, 91]. Statin therapy should be continued in patients already on treatment at the com-
mencement of dialysis—due to the overwhelming evidence of cardiac protection in the non-
dialysis population and paucity of data in the dialysis population [91]. The role for statins 
in dialysis patients post coronary/cerebrovascular event (secondary prevention) and in those 
with LDL > 3.9 mmol/L has not satisfactorily been assessed in RCTs and thus there may 
be a role for therapy in these populations [84, 91].
3.5. Obesity
Higher body mass index (BMI) is associated with higher all-cause and cardiovascular mortal-
ity in the non-dialysis population. In contrast, epidemiological studies in dialysis patients 
Aspects in Dialysis66
have shown a paradoxically inverse association between BMI and mortality [92–97]. HD 
patients appear to have a lower BMI than age and sex-matched controls from the general 
population [98]. The survival advantage associated with a higher BMI appears less in patients 
on PD than on HD [99–101].
Theories to support this paradox include protein energy wasting (PEW), inflammation, com-
peting risk and reverse causation [102]. PEW refers to loss of body protein and fat mass, 
frequently observed in ESKD patients [103]. Increased activation of inflammatory cytokines 
in dialysis patients may cause appetite suppression and proteolysis—overall increasing 
the risk of death from CVD [104]. Obesity may therefore provide a ‘functional reserve’, poten-
tially attenuating the effect of PEW and inflammation in patients with a higher BMI. Given 
the high mortality of patients on dialysis, it may be that the long-term, conventionally det-
rimental effects of obesity may be outweighed by the competing short-term effects of PEW 
and inflammation. Finally, lower BMI may simply be a consequence of conditions that lead 
to poorer outcomes in ESKD, rather than the cause—a confounding factor limited by obser-
vational data [102].
Observational data from Ramkumar et al. showed that PD patients with high BMI/high mus-
cle mass had lower all-cause (HR 0.90, 0.83–0.97) and cardiovascular (HR 0.88, 0.79–0.97) mor-
tality compared with normal BMI/high muscle mass patients [105]. Patients with high BMI/
low muscle mass had an increased risk of all-cause (HR 1.29, 1.17–1.42) and cardiovascular 
(HR 1.21, 1.06–1.39) mortality [105].
The existing evidence is not strong enough to inform decisions regarding weight management 
in ESKD. Larger, prospective, randomised trials are required to assess the efficacy of weight 
management interventions on cardiovascular outcomes in the dialysis population. At this 
stage weight loss measures cannot be recommended for all dialysis patients but increasing 
muscle mass may be beneficial in those on PD.
3.6. Sedentary lifestyle
In an observational study of 2507 incident dialysis patients, 56% reported exercising less than 
once a week and only 20% reported daily exercise [106]. Low aerobic activity has been identi-
fied as one of the strongest predictors of mortality among ESKD patients [107].
Many studies have validated the safety and efficacy of exercise in the CKD population. 
Specifically, trials in dialysis patients have utilised intra-dialytic cycling and/or progressive 
resistance training to show improvements in systemic inflammation, cardiovascular function-
ing, dialysis adequacy and muscle wasting [107]. In an observational study, Stack et al. found 
that mortality risks were lower for dialysis patients who exercised vigorously 2–3 times per 
week (RR 0.74, 0.58–0.95) compared to their less active peers [106]. In a multi-centre ran-
domised trial, Manfredini et al. found that dialysis patients undertaking a personalised walk-
ing program had significantly improved scores on physical (6 minute walk test, 5 times sit 
to stand test), cognitive and quality of life measures [108].
As per Cheema: “despite overwhelming evidence of the safety, efficacy, feasibility and gen-
eralisability of these interventions, as well as comparative trials demonstrating that in-centre 
training results in higher adherence than training on non-dialysis days, intra-dialytic exercise 
Cardiovascular Disease in Dialysis Patients
http://dx.doi.org/10.5772/intechopen.70362
67
remains notably absent from standard practice” [107]. However, it should be noted that high 
quality RCTs evaluating exercise and cardiovascular mortality in ESKD are still lacking.
KDOQI and ISPD guidelines recommend that all dialysis patients be counselled and regu-
larly encouraged to increase their physical activity—accumulating at least 30 min of moderate 
intensity physical activity on most, preferably all days of the week [20, 71]. Patients should 
be appropriately referred for physical therapy to ensure that exercise programs are tailored 
according to functional capacity. It remains uncertain whether aerobic, resistance or combina-
tion programs are most efficacious in dialysis patients.
3.7. Depression
The epidemiology of depression in ESKD is variably reported, largely dependent on the meth-
ods used for screening and diagnosis. A systematic review and meta-analysis of observational 
studies found that the prevalence of depression in HD and PD patients is similar ~40%, higher 
than in CKD (26.5%) or transplant (26.6%) patients [109]. Self-reported diagnostic tools may 
overestimate the prevalence of depression given the overlap of somatic symptoms in ESKD 
(fatigue, anorexia, sleep disturbance) [109].
A meta-analysis of cohort studies (>30,000 dialysis patients) found an increased risk of mor-
tality in patients with depression (RR 1.40, 1.23–1.45, p = 0.03). The risk of increased car-
diovascular mortality was less clear (RR 1.88, 0.84–4.19, p = 0.2) [110]. Randomised trials 
of interventions for depression in CKD have been limited by small sample size, short duration 
and surrogate outcomes to determine efficacy [110].
The KDOQI guidelines recommend that all patients be seen by a social worker at dialysis 
commencement, and at least 6 monthly thereafter to assess their psychosocial state and screen 
for depression and anxiety [20]. The guidelines also recommend treatment for all patients 
with diagnosed depression and/or anxiety. The recommendations are based on moderately 
strong evidence extending from the non-dialysis population.
4. Non-traditional risk factors
4.1. Anaemia
Anaemia is a known complication of CKD, primarily due to the inadequate renal produc-
tion of erythropoietin, with its prevalence increasing as patients’ approach ESKD. Anaemia 
is an established non-traditional cardiovascular risk factor that promotes cardiac structural 
and functional abnormalities including left ventricular hypertrophy/dilatation, diastolic dys-
function, arrhythmias and congestive heart failure [19, 111, 112].
The Dialysis Outcomes and Practice Patterns Study (DOPPS) data showed that approximately 
47% of prevalent HD patients had haemoglobin (Hb) concentrations <110 g/L and 84% were 
prescribed erythropoietin-stimulating agents (ESAs) [113]. DOPPS also found that higher Hb 
concentrations (Hb 110–120 g/L) were associated with decreased mortality (RR 0.95, 0.90–0.99, 
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p = 0.03) and hospitalisation (RR 0.96, 0.93–0.99, p = 0.02) [113]. Similar findings from other 
observational studies may have contributed to the increased ESA use in the US from 1991 
to 2006 [3].
Evidence from RCTs thereafter raised concerns about higher Hb concentrations. CHOIR inves-
tigators reported higher composite CVEs (HR 1.34, 1.03–1.74, p = 0.03) in patients receiving 
ESA who achieved a higher Hb (~135 g/L) when compared with the lower Hb (~113 g/L) target 
group, with no between-group differences in patient reported outcomes [114]. A meta-analy-
sis thereafter by Palmer et al. found that treatment with ESA to a higher Hb target (~130 g/L) 
increased the risk of stroke, worsened hypertension and vascular access thrombosis, compared 
with the lower Hb target (~101 g/L). There were no statistically significant differences between 
groups for the risk of all-cause mortality, serious CVEs or quality of life [115].
The most recent network meta-analysis of RCTs concluded that while ESAs prevent blood 
transfusions, their effect on survival, CVEs and symptom improvement remain unclear. There 
have been few direct comparisons between the different ESAs and the current studies are 
unable to separate the formulations based on patient-centred or hard outcome measures [116].
The KDOQI and KDIGO guidelines currently recommend that ESA therapy be initiated 
when Hb levels are between 90 and 100 g/L, with a view to avoiding concentrations falling 
to <90 g/L. They also suggest that ESAs not be used to maintain Hb concentration > 115 g/L or 
to intentionally increase concentration >130 g/L. Whilst anaemia itself is regarded as a non-
traditional risk factor, its correction with ESA therapy does not appear to improve cardio-
vascular outcomes in dialysis patients. Ultimately dosing and target Hb concentrations very 
much need to be individualised based on patient symptoms and competing co-morbidities. 
The principal goal of ESA therapy is avoidance of blood transfusion.
4.2. Chronic volume overload
Chronic fluid overload remains highly prevalent in dialysis patients and is an independent 
predictor of all-cause and cardiovascular mortality [117, 118].
Zoccali et al. examined chronic fluid exposure using bio-impedance spectroscopy in approx-
imately 35,000 incident HD patients across 26 countries [119]. Baseline fluid overload 
and cumulative 1 year fluid overload exposure predicted excess risk of mortality across all BP 
categories. The highest mortality risk was in those with fluid overload and systolic BP < 130 
mmHg at baseline (HR 1.51, 1.38–1.65, p < 0.001) and at 1 year (HR 1.94, 1.68–2.23, p < 0.001) 
[119]. Fluid overload also independently predicted all-cause mortality (HR 12.98, 1.06–168.23, 
p = 0.042) and a trend of increased CVD mortality (log-rank test 2.90, p = 0.089) in a trial of 307 
PD patients [120]. Interestingly, a multi-centre RCT of 308 patients found that bio-impedance 
did not appear to improve clinical management of fluid status in PD patients [121].
Treatment of fluid overload in dialysis patients has yet to be studied in the RCT setting. However, 
Assimon et al. performed a retrospective analysis of over 118,000 HD patients and found 
that ultrafiltration rates > 13 ml/kg/h were associated with increased mortality (adjusted HR 
1.31, 1.28–1.34) compared with rates ≤ 13 ml/kg/h [122]. As Dasgupta and  colleagues state 
‘controlling the high prevalence of fluid overload in this population is considered an unmet 
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clinical need, and there is a quest for clinical policies specifically aimed at optimising control 
of fluid overload to improve the dim prognosis of patients with ESKD’ [123]. In the interim, 
the traditional goals of sodium and volume restriction (as outlined in Section 3.1) remain key 
to controlling fluid overload and maintaining dry weight in dialysis patients.
4.3. Mineral and bone disorder
Chronic kidney disease—mineral and bone disorder (CKD-MBD) is defined as a systemic 
disorder encompassed by bone abnormalities, laboratory abnormalities and vascular calci-
fication that are associated with hard outcomes such as fractures, cardiovascular morbidity 
and mortality [124]. The premature CVD experienced by ESKD patients is in part due to accel-
erated vascular calcification. With declining renal excretion of phosphorus, its accumula-
tion in serum ultimately promotes the conversion of vascular smooth muscle cells towards 
the osteoblast phenotype [125].
Observational data from >40,000 HD patients showed an incremental association between 
serum phosphorus concentrations and mortality—RR 1.10 (1.02–1.17) and RR 2.47 (1.90–
3.19) at phosphorus levels 1.62–1.78 mmol/L and ≥3.55 mmol/L respectively [126]. Similar 
findings were noted for serum corrected calcium and parathyroid hormone (PTH). 
Hyperphosphataemia and hyperparathyroidism were also significantly associated with all-
cause, cardiovascular and fracture-related hospitalisation.
Many treatment modalities including vitamin D compounds, phosphate binders, cinacalcet, 
bisphosphonates and calcitonin have been successful in correcting the biochemical abnormali-
ties associated with CKD-MBD [127]. However, these therapies have only weakly correlated 
with all-cause and cardiovascular mortality outcomes in a meta-analysis [127]. Furthermore, 
a recent network meta-analysis of randomised trials concluded that there is currently no evi-
dence that phosphate binders reduce mortality compared to placebo [125]. Similarly, a cumu-
lative meta-analysis of 18 RCTs involving 7446 patients with CKD found that cinacalcet did not 
influence cardiovascular or all-cause mortality [128]. There is also no compelling evidence that 
vitamin D influences patient-level outcomes such as CVEs and mortality [129, 130]. Overall, 
existing evidence shows that despite the strong association between bone and mineral param-
eters and CVD mortality in cohort studies, the benefits of drug effects on biochemical targets 
does not translate into improved health outcomes [127].
The KDOQI and KDIGO guidelines do provide recommendations on the evaluation and treat-
ment of the abnormalities of CKD-MBD [131]. However, given the lack of definitive clinical 
outcome trials most of the recommendations are weak and/or discretionary. Further research 
is required to assess whether CKD-MBD is a truly modifiable, non-traditional cardiovascular 
risk factor among dialysis patients.
4.4. Hyperuricaemia
Hyperuricaemia has been associated with increased CVD mortality and CKD progression 
in the non-dialysis population [132–134]. The association between hyperuricaemia and car-
diovascular outcomes in the dialysis population is less clear.
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Latif et al. reviewed DOPPS data and found that higher uric acid levels were associated 
with lower risk of all-cause and CVD mortality in HD patients [135]. The adjusted HR at uric 
acid level ≤ 0.488 mmol/L compared with > 0.488 mmol/L was 1.24 (1.03–1.49) for all-cause 
mortality and 1.54 (1.15–2.07) for CVD mortality. Similar results were found by Bae et al. 
[136]. The authors proposed that elevated uric acid levels among HD patients may be a sur-
rogate marker for better nutritional status, as these patients also had higher serum phosphate 
and BMI [135].
Dong et al. found contrasting results in their multi-centre study of over 2000 PD patients. Each 
1 mg/dL (0.06 mmol/L) increase in uric acid level was associated with higher adjusted all-
cause mortality (HR 1.05, 1.00–1.10) and CVD mortality (HR 1.12, 1.05–1.20). Similar results 
have been found by other authors [137, 138].
Further research is required to shed more light onto the relationship between uric acid 
and cardiovascular outcomes, especially to elucidate the apparent differences in HD 
and PD. Furthermore, it remains to be seen whether correction of uric acid abnormalities may 
alter hard outcomes in the dialysis population.
4.5. Hyperhomocysteinaemia
Homocysteine is a non-essential amino acid that plays an important role in the methionine 
cycle through its interaction with vitamin B12 and folic acid [139]. Disturbance of this path-
way leads to accumulation of homocysteine, which is believed to play a role in vascular cal-
cification, atherothrombosis and CVD [140]. Hyperhomocysteinaemia is seen in 85–100% 
of patients with ESKD and is currently regarded as an independent predictor of CVD mor-
bidity and mortality in this population [139, 141].
Qin et al. performed a meta-analysis of 7 randomised trials involving 3886 patients 
with advanced or ESKD to assess whether homocysteine-lowering with folic acid reduced 
CVE [142]. Folic acid therapy significantly reduced the risk of CVEs (RR 0.85, 0.76–0.96, p = 
0.009), with the greatest benefit seen in patients that had a longer duration of therapy, no or 
partial folic acid fortification and a > 20% decrease in homocysteine levels. However, a subse-
quent meta-analysis of 6 RCTs involving 2452 ESKD patients only found that homocysteine-
lowering therapy had little or no effect on all-cause or cardiovascular mortality [143].
Folic acid therapy for hyperhomocysteinaemia per se is not specifically covered in many dial-
ysis clinical practice guidelines. Folic acid is often supplemented in dialysis patients to avoid 
deficiency, particularly those at risk of malnutrition. Whether folic acid supplementation pro-
vides any additional cardiovascular benefit in replete patients is unknown. Given its cost 
efficacy, favourable side effect profile and potential CVD benefit, it would be reasonable 
to recommend folic acid therapy for ESKD patients not receiving fortification.
4.6. Chronic inflammation—oxidative stress, endotoxaemia and uraemic toxins
Elevated oxidative stress has been associated with increased CVD risk in the ESKD popula-
tion [144]. ESKD patients have been shown to have an imbalance in pro-oxidant and anti-
oxidant pathways that ultimately lead to endothelial dysfunction, chronic inflammation 
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and accelerated atherosclerosis [144]. The predominant mechanism of oxidative stress in HD 
is thought to be through inactivation of nitric oxide synthase by reactive oxygen species [145]. 
Anti-oxidant therapies may therefore have a role in improving CVD outcomes in dialysis 
patients. Tepel et al. performed a randomised, placebo-controlled trial in 134 HD patients 
and found that N-acetylcysteine reduced CVEs (RR 0.60, 0.38–0.95, p = 0.03) but not all-
cause or CVD mortality [146]. Similarly, Boaz et al. evaluated vitamin E in 97 HD patients 
and found that, compared to placebo, vitamin E reduced CVEs (RR 0.46, 0.27–0.78, p = 0.014) 
but had no effect on all-cause or CVD mortality [147]. These findings are yet to be replicated 
in larger clinical trials.
Endotoxaemia has been proposed as a potential mechanism for the chronic inflammation 
seen in ESKD [148]. Endotoxins are complex polysaccharides found on the outer cell wall 
of gram-negative bacteria. Endotoxaemia not only occurs in sepsis, but has also been identi-
fied in congestive heart failure and in ESKD [149–151]. Current endotoxin detection assays 
are however limited by their poor sensitivity and validation in ESKD [152]. Potential sources 
of endotoxaemia that are pertinent to the ESKD population include contaminated dialysate, 
dialysis catheters and circuitry (HD and PD), peritoneal membrane dysfunction, gastrointes-
tinal bacterial translocation and periodontal disease [12, 152]. Preventative strategies such 
as avoidance of temporary dialysis catheters and use of ultrapure water have been shown 
to reduce endotoxin levels [153, 154]. Initial evaluation of gut flora modulation through use 
of pre- and probiotics [155] as well as gastrointestinal decontamination [156] have shown 
some promise—their efficacy is yet to be confirmed in dialysis patients however.
Uraemic toxins, particularly indoxyl sulphate (IS) and p-cresyl sulphate (PCS), have been 
associated with chronic inflammation, premature CVD and mortality in ESKD [157–160]. 
Both toxins are produced by large bowel microbiota, which is known to be dysregulated 
in CKD and ESKD [161]. In a meta-analysis of 10 RCTs involving 1572 patients with CKD, 
PCS was significantly associated with both all-cause mortality (OR 1.16, 1.03–1.30, p = 0.013) 
and cardiovascular mortality (OR 1.28, 1.10–1.50, p = 0.002) whereas IS was only significantly 
associated with all-cause mortality (OR 1.10, 1.03–1.17, p = 0.003) [157]. Importantly, there is 
limited but supportive evidence for the effectiveness of pre- and probiotics on reducing IS 
and PCS levels in CKD [161, 162]. Whether this translates to improved cardiovascular out-
comes in the dialysis population remains to be seen.
5. Cardiovascular disease screening
Despite the considerable burden of CVD in the ESKD population, screening in asymptomatic 
individuals is not routine in clinical practice, except those being evaluated for transplantation. 
This may in part be due to the uncertainty regarding whether early detection and interven-
tion improves outcomes in this population. Furthermore, CVD screening methods in them-
selves pose unique challenges in the dialysis cohort. The prediction of CAD risk is limited by 
traditional risk estimate tools, including the Framingham risk model, which can underesti-
mate risk in ESKD by 50% [163]. The biomarkers and screening tests with the most evidence 
in ESKD are presented here. A summary of the limitations of screening tests in the dialysis 
population are shown in Table 2.
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5.1. Biomarkers
The search for a novel predictive biomarker has not yielded many successful results. Markers 
of myocardial injury, inflammation, endothelial dysfunction, sympathetic overactivity, oxida-
tive stress and atherosclerosis have been evaluated [165]. The most promising biomarker appears 
to be the cardiac troponin assay. A meta-analysis of ~4000 asymptomatic ESKD patients found 
that an elevated troponin T level (>0.1 ng/ml) was significantly associated with increased all-
cause mortality (RR 2.64, 2.17–3.20) and CVD mortality (RR 2.55, 1.93–3.37) [166]. The American 
College of Cardiology Foundation highlighted the value of troponin for prognostication 
in ESKD but also its current limitations in guiding clinical practice [167]. This may be in part 
related to the lack of specificity of troponin, elevated in more than a third of patients with ESKD 
[165]. B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT pro-BNP) may also have 
a role in predicting CVD and all-cause mortality in ESKD [168]. The between-person variability 
of NT pro-BNP is considerable in stable HD patients, likely accounted for by differences in fluid 
status, residual kidney function, dialysis prescription and underlying cardiac pathologies [169]. 
However, the within-person variation is markedly smaller and thus may be of greater prognos-
tic significance [169]. In a prospective cohort study of baseline serum NT pro-BNP levels in 230 
PD patients, the adjusted HR for all-cause mortality and cardiovascular mortality of the fourth 
quartile were 4.97 (1.35–18.28, p = 0.016) and 7.50 (1.36–41.39, p = 0.021) respectively, compared 
with the first quartile [170]. Similar results were found in a study of 150 HD patients, where 
serum NT pro-BNP had a strong graded relationship with all-cause mortality (HR 1.54, p < 0.01) 
and cardiovascular mortality (HR 2.99, p < 0.01) [171]. Furthermore, a prospective cohort study 
of 113 HD patients found that an annual increase in serum BNP of 40% predicted all-cause 
and cardiovascular death in the subsequent year [172].
5.2. Exercise stress test
Exercise stress testing is generally a poor screening tool in the dialysis population given the high 
prevalence of baseline ECG abnormalities, limited exercise tolerance due to  non-cardiac 
 co-morbidities, a blunted chronotropic response from autonomic dysfunction—ultimately 
only 7–53% of patients achieve the target heart rate [164].
Non-invasive screening test Limitations in ESKD
Exercise stress test Poor exertional tolerance
High prevalence of baseline ECG abnormalities
Myocardial perfusion scintigraphy Low sensitivity
Dobutamine stress echocardiography Operator dependent
Adequate acoustic windows not possible in up to 20% of cases
Coronary artery calcium score No correlation between score and CAD
CT coronary angiogram Contrast exposure
Low specificity due to high coronary calcium burden
Cardiac MRI Inability to use gadolinium
Adapted from [164].
Table 2. Limitations of non-invasive screening methods in ESKD patients.
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5.3. Myocardial perfusion scintigraphy (MPS)
Myocardial blood flow can be evaluated both at rest and post cardiac stress with MPS. The same 
limitations of exercise stress testing exist with exercise-MPS in dialysis patients, necessitating 
the use of pharmacological stressors. When compared to coronary angiography, its specificity 
and sensitivity range from 37 to 100% and 29 to 92%, respectively. The low sensitivity in dial-
ysis patients has been attributed to equally distributed diminished coronary flow (‘balanced 
ischaemia’) and an impaired vasodilatory response [164]. Nevertheless, an abnormal MPS 
finding was a significant independent predictor of CVEs (HR 2.11, 1.05–4.24, p = 0.035) [173]. 
In one prospective study of 150 dialysis patients, an abnormal MPS result was more predic-
tive of mortality than the number of narrowed coronary vessels [174].
5.4. Dobutamine stress echocardiography (DSE)
DSE demonstrates resting and stress-induced regional wall motion abnormalities which sig-
nify scar and ischaemia respectively [165]. DSE is a valid screening test as it not only provides 
information on the location and extent of CAD, but also on ventricular hypertrophy, volume 
status and valvular disease. Its sensitivity and specificity appear similar to that of MPS [164]. 
An abnormal DSE result had a HR of 4.3 (1.8–10.0) for major CVE, with similar findings across 
many studies in ESKD [175–178].
5.5. Coronary artery calcium score
Computed tomography (CT) is a sensitive tool for the detection and quantification of calcium 
deposition in soft tissues, particularly coronary arteries. Coronary calcium scores do predict 
mortality in dialysis patients, but have poor correlation with angiogram findings [179, 180]. 
Though not the best tool to predict future need for coronary intervention, low or negative 
coronary calcium scores have been shown to have good negative predictive value [180].
5.6. CT coronary angiogram
CT coronary angiogram is presently used in the general population to evaluate CAD in low 
to intermediate risk patients. Its utility has not been extensively assessed in the dialysis pop-
ulation. In a trial of 70 maintenance HD patients, the prevalence of CAD on CT coronary 
angiogram at baseline was 43%. After 2 years, 36% of those with CAD had a CVE compared 
with none of the patients with no significant CAD (p < 0.01) [181]. Given its high negative 
predictive value, Hakeem et al. concluded that ‘the potential role of CT coronary angiogram 
likely rests in serving as a gatekeeper for invasive angiography in patients with submaximal, 
equivocal or mildly abnormal stress tests’ [165].
5.7. Coronary angiography
Coronary angiography remains the gold standard for the diagnosis of CAD in dialysis patients. 
Its use as a screening tool is limited by its cost, invasive nature and presumed deleterious effects 
on residual kidney function [164]. CAD (>50% coronary stenosis) has been identified in 50–70% 
of asymptomatic incident HD patients, with multi-vessel involvement in up to 40% [182–184]. 
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Coronary intervention does not appear to improve survival in asymptomatic individuals 
in the general population [185]. Yasuda et al. performed a prospective cohort study over 5 years 
in 259 HD patients with CAD to assess whether percutaneous intervention had a therapeutic 
advantage over medical therapy [186]. They found that after adjustment for other risk factors, 
effects of coronary intervention on the risk for all-cause mortality (OR 0.37, 0.26–0.54, p = 0.006) 
and CVD mortality (OR 0.14, 0.08–0.25, p < 0.001) remained significant and independent [186]. 
This evidence clearly needs to be clarified further through larger and ideally randomised trials.
As for any screening program, the expected benefits should outweigh the costs and side 
effects. Screening can only be justified when there is high asymptomatic disease prevalence 
within the cohort and with evidence that early intervention improves overall outcomes [164]. 
Early coronary intervention should be the focus of future research, which may alter screening 
practices in ESKD. Hakeem et al. proposed an algorithm for CAD screening and risk strati-
fication in asymptomatic ESKD—the adapted schematic is presented below [165] (Figure 1).
6. Screening in renal transplant candidates
Patients with ESKD being considered for transplantation warrant comprehensive cardiac evalua-
tion to assess both peri-operative and post-transplant risk. CVD remains the major cause of mor-
tality after renal transplantation, with approximately 30% due to myocardial infarction [187, 188]. 
Figure 1. Proposed algorithm for CAD screening. Modified from [165]. ESKD, end-stage kidney disease; LV, left 
ventricular; CACS, coronary artery calcium score; CTCA, CT coronary angiogram.
Cardiovascular Disease in Dialysis Patients
http://dx.doi.org/10.5772/intechopen.70362
75
Several workgroups have published guidelines and recommendations regarding the cardiac 
workup of dialysis patients awaiting transplantation. A summary of the recent guidelines is pre-





• all candidates for kidney transplantation be screened for CVD risk factors. Indicators of high risk 
include: older age, DM, abnormal ECG, prior IHD or CCF, increased dialysis vintage, smoker
• stress testing such as MPS or stress echocardiography be performed without concurrent 
β-blocker therapy
• coronary angiography for candidates with abnormalities on screening procedures
Suggest that:
• candidates with low CVD risk do not require stress testing for CAD
• candidates with a moderate or high clinical risk of CVD undergo stress testing prior 
to transplantation
• the prognostic accuracy of cardiac stress testing diminishes after 24 months. The interval at 
which testing should take place not been well defined
• the benefit of revascularisation prior to transplantation be reviewed on an individual basis
2012 ACC/AHA
[190]
• Non-invasive stress testing may be considered in those with no active cardiac conditions: 
presence of multiple CAD risk factors regardless of functional status
• Relevant risk factors include DM, prior CVD, > 1 year on dialysis, LV hypertrophy, age > 60 
years, smoking, hypertension, dyslipidaemia. Reasonable to prompt stress testing with ≥ 3 
risk factors
• The usefulness of periodically screening asymptomatic subjects for ischaemia while 
on the waiting list to reduce the risk of CVE is uncertain
2005 NKF KDOQI
[20]
Non-invasive stress testing recommended for:
• all patients with DM; repeat every 12 months
• all patients with prior CAD:
• If not revascularised, repeat every 12 months
• If prior PCI, repeat every 12 months
• If prior CABG, repeat after first 3 years and then every 12 months
Repeat every 24 months in “high-risk” non-diabetic patients defined as:
• ≥2 traditional risk factors
• known history of CAD
• LVEF ≤ 40%
• peripheral vascular disease
KHA-CARI, Kidney Health Australia Caring for Australasians with Renal Impairment; ACC/AHA, American College 
of Cardiology/American Heart Association; NKF KDOQI, National Kidney Foundation Kidney Disease Outcomes Quality 
Initiative; CVD, cardiovascular disease; DM, diabetes mellitus; IHD, ischaemic heart disease; CCF, congestive cardiac 
failure; MPS, myocardial perfusion scintigraphy; CAD, coronary artery disease; LV, left ventricular; CVE, cardiovascular 
events; PCI, per cutaneous intervention; CABG, coronary artery bypass grafting; LVEF, left ventricular ejection fraction.
Table 3. Summary of cardiac screening guidelines for the patient with ESKD awaiting renal transplantation.
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7. Conclusion
The high incidence of multiple traditional and non-traditional risk factors predisposes dialy-
sis patients to a considerable burden of CVD. This chapter has summarised the available evi-
dence supporting CVD risk factor modification, prevention and screening in ESKD. Clinicians 
must appreciate the limitations of the current evidence and tailor specific therapeutic strate-
gies to the individual patient. Future research into modifiable, non-traditional risk factors is 
warranted and we look forward to their clinical application and improvement of CVD out-
comes in ESKD.
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